Parkinson's Disease Dementia: Diagnosis and Management

Dementia is one of the most consequential non-motor features of Parkinson's disease. Around a quarter to a third of people with Parkinson's develop it, and the likelihood rises with disease duration and age. It affects independence, caregiver burden and life expectancy more than tremor or stiffness, yet it is often attributed to "just getting older" or to depression and left unaddressed. The Chinese guideline on Parkinson's disease dementia (second edition) sets out diagnostic criteria and practical management.

Recognising the pattern

Parkinson's disease dementia is defined as dementia developing in a person who already has established Parkinson's disease — the movement disorder comes first, typically by more than a year. The cognitive profile is distinctive and differs from Alzheimer's: executive dysfunction (planning, sequencing, mental flexibility) and visuospatial difficulty dominate, while memory is impaired mainly in retrieval rather than storage. Attention fluctuates, thinking is slowed (bradyphrenia), and apathy, hallucinations and daytime sleepiness are common companions. Practical bedside tools recommended by the guideline include the pill questionnaire — can the patient accurately describe their medicines, doses and timing — as a direct test of whether cognition affects daily function, and the Neuropsychiatric Inventory for behavioural symptoms, with scores of three or more on an item generally treated as clinically significant.

Ruling out look-alikes

Several conditions mimic dementia in Parkinson's and must be excluded or treated first: depression, which impairs concentration and motivation; delirium from infection or medication; sleep disorders and excessive daytime sleepiness; psychosis and hallucinations, which may be drug-induced; and the cognitive side effects of medication itself — anticholinergic drugs, amantadine, and dopamine agonists, which can cause impulse-control disorders and confusion. Blood tests to exclude thyroid or vitamin B12 deficiency, and imaging to exclude hydrocephalus or significant vascular disease, are part of the standard work-up.

Treatment

The most effective pharmacological treatment is a cholinesterase inhibitor — rivastigmine, donepezil or galantamine — which produces modest but real improvements in cognition, attention and daily function, and may reduce hallucinations and apathy. Memantine is an option, particularly where cholinesterase inhibitors are not tolerated. Management of hallucinations may require adjusting Parkinson's medication rather than adding an antipsychotic — quetiapine and clozapine are the antipsychotics least likely to worsen parkinsonism, and typical antipsychotics should be avoided. Physical exercise, physiotherapy and cognitive training have supporting evidence, and treating depression, sleep and orthostatic hypotension improves cognition indirectly.

Caregiver support

Families carry most of the burden, and the guideline is explicit that supporting them is part of treatment. Practical measures include: simplifying the medication schedule with a pill organiser or supervised dosing; establishing routines; removing driving when judgement and visuospatial function are impaired; assessing falls risk and adapting the home; dealing with finances, advance directives and legal arrangements while the person can still participate; and giving carers respite and access to support services. Hallucinations and sleep disturbance at night are the symptoms most often cited by carers as hardest to manage, and both are treatable.

What to ask

Ask which cognitive domains are affected, what the likely trajectory is, and whether any current medicine is contributing. Ask for a written plan covering medication simplification, driving, falls and future decision-making — and ask to be reviewed at defined intervals, because both the cognitive and the behavioural picture change over time.